US officials head to Berlin for drug pricing talks

Tłumaczenie nie jest jeszcze gotowe. Wyświetlamy oryginalny artykuł.

Senior U.S. trade and health officials are expected to meet with the German government in mid-November for talks on its drug pricing policies, a German government spokesperson confirmed to POLITICO. The talks come as Germany races to avoid U.S. tariffs if it does not reach an agreement with Washington — after the Trump administration launched a trade investigation into Berlin’s pricing policies in June. The Trump administration alleges Germany underpays for new drugs, leaving the U.S. to shoulder a disproportionate share of the global cost of developing innovative medicines. As part of consultations required under Section 301 probes, a meeting between U.S.